MUNDIPHARMA has confirmed the availability of its Nyxoid intranasal naloxone spray, which can now be stocked in pharmacies for over-the-counter sale.
The S3 opioid reversal agent was registered by the TGA late last year, and will also be considered by the Pharmaceutical Benefits Advisory Committee next month for funding as an unrestricted listing for known or suspected opioid overdose.
Mundipharma said it was in discussion with a number of state and territory governments about possible ways the take-home opioid reverser could become available at no cost to at-risk communities.
Jarror McMaugh, pharmacist and Harm Reduction Victoria board member, said the availability of a discreet nasal spray that requires minimal training was an important development for people at risk of opioid overdose.
A twin pack of Nyxoid will retail for $75-$85.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Feb 19
